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Abstract: Next-generation sequencing (NGS) is a cost-effective technology capable of screening
several genes simultaneously; however, its application in a clinical context requires an established
workflow to acquire reliable sequencing results. Here, we report an optimized NGS workflow
analyzing 22 lung cancer-related genes to sequence critical samples such as DNA from formalin-fixed
paraffin-embedded (FFPE) blocks and circulating free DNA (cfDNA). Snap frozen and matched FFPE
gDNA from 12 non-small cell lung cancer (NSCLC) patients, whose gDNA fragmentation status
was previously evaluated using a multiplex PCR-based quality control, were successfully sequenced
with Ion Torrent PGM™. The robust bioinformatic pipeline allowed us to correctly call both Single
Nucleotide Variants (SNVs) and indels with a detection limit of 5%, achieving 100% specificity and
96% sensitivity. This workflow was also validated in 13 FFPE NSCLC biopsies. Furthermore, a specific
protocol for low input gDNA capable of producing good sequencing data with high coverage, high
uniformity, and a low error rate was also optimized. In conclusion, we demonstrate the feasibility of
obtaining gDNA from FFPE samples suitable for NGS by performing appropriate quality controls.
The optimized workflow, capable of screening low input gDNA, highlights NGS as a potential tool in
the detection, disease monitoring, and treatment of NSCLC.
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1. Introduction
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death worldwide, and
the majority of patients are diagnosed at advanced stages of NSCLC, with a dramatically poor five-year
overall survival rate of 15% [1].
Recently, the identification of the molecular pathology of individual patient tumors has emerged as
a promising opportunity for treatment of patients affected by advanced disease. Indeed, specific genetic
alterations that drive cancer development can be targeted by selected inhibitors. In particular, the
signaling pathway downstream of the Epidermal Growth factor Receptor (EGFR) has been investigated
in advanced NSCLC patients harboring activating EGFR mutations (approximately 15% of Caucasian
and 50% of Asian patients) treated with first-line tyrosine kinase inhibitors (TKIs), such as gefitinib,
erlotinib, and afatinib. These patients report significant improvement in response and progression-free
survival compared with patients treated with traditional chemotherapy [2].
Additionally, the application of molecular-based targeted approaches directed to other driver
mutations, such as KRAS, BRAF, and the PI3K/AKT/mTOR pathway, is currently under evaluation,
and several trials have been designed to assess the pharmacological efficacies of these compounds,
reporting encouraging results [3].
Currently, traditional tools such as Sanger Sequencing (SS), real-time PCR, and pyosequencing
(PS) can screen mutations on few genes per run with a sensitivity of approximately 20%, 10%,
and 1%–2%, respectively [4–7]. However, the increasing number of novel potential targets results in
more time-consuming and expensive diagnostic tests [8]. The advent of NGS has revolutionized the
approach to detect gene mutations but requires high-quality DNA. The majority of advanced NSCLC
tumor samples are usually represented by FFPE biopsies that result in limited quantity and low-quality
DNA, affecting NGS feasibility. Recently, the evaluation of mutations in circulating free DNA (cfDNA)
in the plasma of patients affected by advanced NSCLC has emerged as a hypothetical alternative
approach to detect gene mutations from a liquid biopsy [9]. However, the feasibility of performing
NGS on critical samples remains challenging, and increased efforts should be made in this direction to
offer the best individual therapeutic option.
Here we present an optimized workflow to perform deep sequencing using the Ion AmpliSeq
Colon and Lung Cancer Panel v.1 (Life Technologies, Carlsbad, CA, USA), which analyzes hotspot and
targeted regions of 22 genes frequently mutated in colon and lung cancer. Analyses were performed
on DNA resulting from critical samples, such as FFPE biopsy blocks and cfDNA, including a quality
control step to assess the DNA quality from these samples.
2. Results
2.1. Assessment of NGS (Next-Generation Sequencing) Detection Limit, Specificity, Sensitivity, and Positive
Predictive Value
gDNAs obtained from FFPE sections of engineered cell lines with clinical relevant mutations
in tyrosine kinase domain of EGFR, such as p.T790M and the p.Glu746_Ala750del, were used to
assess the limit of detection (LOD) of our NGS workflow. Firstly, dilution series of p.Thr790Met
EGFR mutated gDNA with wild-type EGFR gDNA were used to obtain mutant allele frequencies
of 50%, 10%, 5%, and 1%, respectively. All dilutions underwent to library preparation and sequenced
by Ion PGM, achieving an average coverage per amplicon >1200ˆ and uniformity >96% across
the samples. Notably, the p.Thr790Met EGFR mutation was detected up to the third dilution (5%)
with allele frequencies of 49.6%, 10.7%, and 5.6%, respectively, whereas the call of p.Thr790Met
mutation was missed in the lowest dilution (1%). Similarly, we also assessed the LOD of our assay
to correctly call the indel, applying a serial dilution of the p.Glu746_Ala750del gDNA with EGFR
wild type, confirming the previous LOD of 5% also for indel detection. To evaluate the specificity,
sensitivity, and Positive Predictive Value (PPV), we also sequenced two NSCLC cell lines (NCI-H1650
and NCI-H1975) and the two reference standards with EGFR mutation at 50% of frequency. NGS
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data analysis revealed a specificity of 100% for the detection of SNVs and INDELs compared to the
genotypes of NCI-H1650 and NCI-H1975 cell lines (genotype data assessed by Coco et al., using
NGS platform) and the two FFPE reference standards (genotype data assessed by Horizon using
Droplet Digital PCR), whereas the sensitivity for detecting variants at the LOD of 5% was 96%
(Confidence Interval (CI) 95% = 80.5, 99.3) with PPV of 100% (95% CI = 86.7, 100.0).
2.2. FFPE (Formalin-Fixed Paraffin-Embedded) Quality Control
gDNA from FFPE tissues reported very high purity (both 260/280 and 260/230 ratios > 1.7) and
underwent multiplex PCR-based quality control assay, with degradation status ranging from 0.3 to 0.8
Average Yield Ratio (AYR). To identify an AYR cut-off suitable for library preparation, we chose three
FFPE DNA samples with different AYR values (0.3, 0.6, and 0.8) and prepared the libraries starting
from 10 and 20 ng of gDNA. As expected, all samples were successfully amplified when starting
from 20 ng, whereas only two out of three were amplified when starting from 10 ng; indeed, the sample
that did not show any amplification products was the most fragmented (0.3 AYR, corresponding to 70%
degradation). Additionally, to set the gDNA degradation status cutoff, as a prerequisite for proceeding
to a downstream workflow, we increased the fragmentation status of gDNA with the lowest AYR (0.3)
by heat. In more detail, by adjusting the fragmentation time we obtained a gDNA test with AYR of
0.2 that was amplified starting from 20 ng as input DNA for the library construction. However, this
sample did not display any amplification products, suggesting that 0.3 AYR was a reliable decision
criterion to predict the NGS suitability of FFPE samples.
Then, to evaluate the degradation effect on sequencing output, all positive libraries were
sequenced. Notably, the sample with 0.6 AYR, although successfully amplified starting from 10
and 20 ng of gDNA, displayed much higher coverage (2/90 amplicons < 500ˆ) using 20 ng compared
with 10 ng (6/90 amplicons < 500ˆ). Therefore, we decided to use a DNA input of 20 ng for the library
construction of all FFPE DNA samples.
2.3. FFPE and Snap Frozen (SF) NGS
Twelve FFPE (AYR range 0.3–0.8) and matched SF gDNAs were sequenced. The coverage and
uniformity of each sample run are reported in Supplementary Table S1. The total number of reads
was 6,993,993 and 6,538,054 for SF and FFPE samples, respectively. NGS analysis disclosed an
average number of reads per amplicon of 6475.9 in SF samples compared with 6050.5 in FFPE
samples. Despite this high coverage, seven of 12 FFPE samples revealed at least one amplicon
(range: 1–5) with coverage less than 500ˆ, whereas only one SF sample showed one amplicon with
unsatisfactory coverage. More specifically, the FFPE sample ID12 with an AYR = 0.3, showed 19
amplicons with a coverage <500ˆ, suggesting that low quality of gDNA could affect sequencing
results. Notably, the aforementioned seven FFPE DNAs reported recurrent amplicons not fully covered:
AKT1_1 (chr14: 105246446-105246583), FGFR3_2 (chr4: 1806082-1806187), NOTCH1_1 (content;
chr9: 139399338-139399447), STK11_3 (chr19: 1220481-1220603), and TP53_2 (chr17: 7579351-7579485).
Interestingly, these amplicons displayed high GC content (greater than 61%). Notably, the coverage
uniformity also correlated with gDNA fragmentation status; more specifically, all SF samples
displayed 100% coverage uniformity, except for one with 98.9%, whereas FFPE samples ranged
from 73.3% to 100%, referring to 0.4 and 0.8 AYR samples, respectively.
The Variant Caller (VC) plugin reported a total of 102 genetic variants (100 SNVs and two indels)
(Supplementary Table S2). Notably, all the EGFR and KRAS mutations previously detected by SS were
confirmed in all NSCLC samples reporting identical results starting from SF and matched FFPE tissue,
although with different allele frequencies due to intra-tumor heterogeneity (Table 1), whereas the other
seven genes present in the colon-lung panel showed discordant results between FFPE and matched SF
samples. In particular, 11 discordant nucleotide substitutions were identified: six genetic variants at a
frequency less than 5% (1 in SF; 5 in FFPE), and five ranging from 5% to 20% (three in SF; two in FFPE)
(Supplementary Table S3).
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Table 1. EGFR and KRAS mutational status comparison between Sanger Sequencing and NGS (Next-Generation Sequencing) Variant Caller software. This table
reports the EGFR or KRAS mutational status, previously defined by Sanger Sequencing from the 12 patients compared to the Variant Caller NGS results. The EGFR or
KRAS mutation nomenclature is based on the convention recommended by the Human Genome Variation Society [10,11].
Patient Tumor Type EGFR and KRAS Status by Sanger Sequencing EGFR and KRAS Status Confirmed by VC Software Allele Name
1 SF
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Table 1. Cont.
Patient Tumor Type EGFR and KRAS Status by Sanger Sequencing EGFR and KRAS Status Confirmed by VC Software Allele Name
6 FFPE
















































NM_033360.3 (KRAS): c.34G>T Confirmed KRAS mutation
COSM516
(p.Gly12Cys) AF: 42.6%
Abbreviations: SF: Snap Frozen; FFPE: Formalin-Fixed Paraffin-Embedded; VC: Variant Caller; AF: Allele Frequency.
28769
Int. J. Mol. Sci. 2015, 16, 28765–28782
To confirm the Single Nucleotide Variants (SNVs) (excluding indels) identified by the VC software,
we performed a second round of analysis using the GATK software, which identified 103 nucleotide
substitutions. Notably, GATK validated 93 SNVs identified by VC: 89 FFPE-SF matching SNVs and
four of five VC-SNVs (5%–20% frequency) FFPE-SF non-matching, reported as pathogenic mutations
(COSM516; COSM1579024; COSM710; COSM11496). Conversely, this pipeline did not confirm the
six VC-SNVs (<5% frequency) and one VC-SNV (5%–20% frequency). Moreover, the GATK software
identified an additional 10 non-matching novel SNVs (six with a frequency <20% and four with a
frequency higher than 20%; range: 20%–35%). However, since none of those four (>20%) was confirmed
by SS, we consider them as false positives (data not shown).
We also applied the PS to further validate the five genetic variants (5%–20% frequency) discordant
between the FF and matching FFPE samples, confirming all VC-SNVs as true positives (Supplementary
Table S3). Overall these data suggest the superiority of the VC pipeline to the call genetic variants
generated by Ion PGM. Therefore, we considered 94 SNVs and two indels called by VC to define
the tumor samples’ mutational profile, excluding six genetic variants at a frequency lower than 5%,
according to our assay LOD.
Data reported an average of 7.4 genetic variants (range 5–12) per patient, including Single
Nucleotide Polymorphisms (SNPs) and pathogenic mutations. More specifically, only two SNPs
involving the DDR2 intron region (rs200983597 and rs143729297) reported a Minor Allele Frequency
(MAF) smaller than 0.01 defined as “rare” variants [12]. Among the pathogenic variants (Figure 1A),
tumor protein p53 (TP53) was the most altered gene: five out of 12 patients harbored pathogenic
mutations (COSM44571; COSM43814; COSM45413; COSM40942; COSM10769) and all reported a
SNP (rs1042522). Additionally, five patients harbored MET proto-oncogene receptor tyrosine kinase
(MET) gene mutations (COSM706; COSM710; COSM1579024). Notably, COSM710 and COSM1579024
coexisted with KRAS mutations (COSM518; COSM520; COSM516). Further somatic mutations
involved the serine/threonine kinase 11 (COSM49004), catenin (cadherin-associated protein) beta 1
(COSM5670), and SMAD family member 4 (COSM14151).
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Figure 1. Somatic Variants identified in the “Training Set” (A) and in the “Validation Set” (B), 
respectively. The pie charts report the frequency of mutated genes in the “Training Set” (A) and in 
the “Validation Set” (B) based on the Catalogue of Somatic Mutation in Cancer (COSMIC) [13]. 
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13 NSCLC patients, previously tested for EGFR mutational status by SS in order to validate our 
Figure 1. Somatic Variants identified in the “Training Set” (A) and in the “Validation Set” (B),
respectively. The pie charts report the frequency of mutated genes in the “Training Set” (A) and
in the “Validation Set” (B) based on the Catalogue of Somatic Mutation in Cancer (COSMIC) [13].
Finally, to correctly call genetic variants also including indel, we sequenced a further cohort of 13
NSCLC patients, previously tested for EGFR mutational status by SS in order to validate our optimized
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workflow and test the ability of the bioinformatic pipeline. All gDNA underwent to a multiplex-PCR
quality control step, reporting AYR values greater than 0.3, predictive of NGS suitability. Then all
FFPE gDNAs were subjected to the Ion PGM workflow and successfully sequenced. In particular, the
data analysis properly called four EGFR variants detected by SS. Similarly to the training set, the data
analysis identified a mean of 7.0 genetic variants (ranging from five to 10) per patient, and, besides
the EGFR activating mutations, we identified further pathogenic variants involving BRAF, CTNNB1,
KRAS, MET, PI3KCA, and TP53 genes (Figure 1B).
2.4. cfDNA NGS
Plasma samples, collected at diagnosis, were available for nine out of 12 patients for cfDNA
extraction. Quantification of cfDNA was evaluated by qPCR using the hTERT assay, showing total
concentrations ranging from 0.08 to 10 ng. Because the gDNA input recommended for library
construction is 10 ng, we used a Whole Genome Amplification (WGA) technique to increase the starting
cfDNA amount. First, we evaluated the WGA technique performance by a scalar dilution of NCI-H1650
human cell line gDNA (10, 1, and 0.1 ng), reporting final gDNA yields of approximately 20 µg regardless
of the starting gDNA input. Then, 10 ng of each WGA NCI-H1650 was sequenced to evaluate the
specificity and sensitivity of the WGA technique. The sequencing outputs reported a coverage of WGA
gDNA greater than 500ˆ and uniformity of 95.2%, except for the WGA 0.1 ng input gDNA sample that
displayed four unsatisfactory covered amplicons and a uniformity of 81.1%. The NGS data analysis
showed an optimum variant call concordance and identical results in terms of frequencies of variant calls
starting from 10, 1, and 0.1 ng of NCI-H1650 gDNA (data not shown). However, the comparison between
WGA and the original unamplified NCI-H1650 gDNA displayed five novel insertions in common
among all WGA samples. Because these insertions occurred in homopolymeric regions (five or more
nucleotide repeats), we hypothesized them to be amplification artefacts due to the WGA technique.
Additionally, four out of five novel insertions displayed an AF lower than our LOD (5%); therefore, these
insertions were excluded from the performance analysis of NGS workflow on WGA samples resulting in
specificity, sensitivity, and PPV of 87.5% (CI 95% = 52.9, 97.7), 100.0% (CI 95% = 67.5, 100), and 100.0%
(CI 95% = 67.5, 100), respectively. Therefore, due to the introduction of amplification artefacts in WGA
cell lines, we decided to limit the use of the WGA approach to the three samples characterized by low
input cfDNA (<1 ng). The remaining six samples were then enriched starting from a lower amount of
recommended input cfDNA (2–10 ng) by increasing the cycle number of library PCRs. This modified
protocol allowed us to obtain suitable no-WGA libraries; the coverage and uniformity of each run are
displayed in Supplementary Table S1.
Although the average reads per amplicon for WGA cfDNA was higher compared with no-WGA
cfDNA samples (6719.7 vs. 4858.5), the coverage uniformity was better in the no-WGA cfDNA;
more specifically, WGA cfDNA showed an average of 83.7% (81.1%–85.6%) vs. 99.4% of the
no-WGA (98.9%–100%). Indeed, no-WGA cfDNA sample exhibited coverage greater than 500ˆ
for all amplicons, except for one sample with 64 amplicons<500ˆ, likely because of a low input of
cfDNA (2.1 ng). Conversely, WGA cfDNAs always displayed five amplicons with coverage less
than 500ˆ. Notably, as previously observed in the seven FFPE samples, the recurrent uncovered
amplicons (AKT1_1, FGFR3_2, NOTCH1_1, STK11_3, and STK11_5) contained high GC-content.
Data obtained from VC were compared to the matched tumor mutational profile. As expected, the
WGA cfDNA displayed additional insertions; notably, these insertions, likely due to non-specific
amplification artefacts of WGA, were the same observed in the NGS analysis of WGA NCI-H1650
and therefore filtered out. Moreover, the comparison analysis identified two additional SNVs
with frequencies of 4.4% and 20.6%. However, the second variant call by GATK (Supplementary
Table S4) validated all SNVs identified by VC, excluding the nucleotide variant below 5%. Although
the remaining discordant variant (20.6%) was confirmed by GATK, it occurred in a WGA-cfDNA
sample, suggesting a possible PCR artefact. Unexpectedly, eight out of nine cfDNAs did not disclose
any somatic mutations either in the gatekeeper gene TP53 or in the other genes mutated in their
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matched tumors; by contrast, one cfDNA from a patient with metastatic disease presented the identical
mutational profile reported in the corresponding tumor.
3. Discussion
Recently, targeted therapy has emerged as a promising therapeutic option for the subgroup
of advanced NSCLC patients carrying activating mutations in druggable genes [2]. Currently, the
screening of clinically-actionable mutations is performed on FFPE tumor biopsies, but the amount
of tumor tissue is often limited, and the gDNA quality may not be always optimal. Moreover,
the increasing number of candidate targets requires the validation of highly sensitive throughput
technologies, such as NGS, into clinical settings. To date, several studies have investigated targeted
deep sequencing on FFPE samples from different cancer types [14–16], including NSCLC [17]; here, we
propose an optimized workflow using a specific 22-gene enrichment lung cancer panel to successfully
sequence critical samples, such as FFPE biopsies and cfDNA, assuring good quality of NGS data.
The workflow includes correct quantification and quality control of input gDNA, a WGA approach
to linearly increase the gDNA for low input of starting gDNA (<1 ng), library protocols tailored for
specific gDNA type (FFPE and cfDNA), and a robust bioinformatic pipeline to correctly call both
SNVs and indels (Figure 2). Similarly to other NGS workflows [18], our assay was able to detect up to
5% of AF either SNV and indel, achieving an optimal assay performance for FFPE samples (100% of
specificity and PPV; 96% of sensitivity). The NGS workflow was retrospectively evaluated on DNA
extracted from SF and matching FFPE and cfDNA belonging to 12 resected NSCLC patients previously
tested for EGFR and KRAS mutations by SS.
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Fixed Paraffin-Embedded); (B) SF (Snap Frozen); and (C) Plasma. These workflows, currently 
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common among three workflows, includes: Ion PGM sequencing and variant identification using VC 
software and then GATK for SNVs call. The NGS cost (from DNA extraction to NGS data analysis), 
excluding personnel, is approximately 250€ for each FFPE, SF, and plasma sample (A–C). The NGS 
turnaround time for processing SF (B) and no-WGA cfDNA (C) samples is approximately five days, 
whereas for FFPE (A) and WGA cfDNA (C) samples one more day is required for the multiplex PCR 
DNA quality control (A) and WGA technique (C). 
Pre-analytic quality control to define suitable DNA for NGS application is crucial, particularly 
when it is applied to highly degraded DNA, such as FFPE DNA. The majority of studies, aimed to 
define FFPE deep sequencing guidelines, focused on the correct DNA quantification method [19,20], 
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currently designed for the Ion PGM pl tform, are divided into five steps: DNA extraction,
gDNA Quality, gDNA Quantity, NGS Template preparation, and NGS sequencing and data
analysis. The latter, in common among three workflows, includes: Ion PGM sequencing and variant
identification using VC softwar a d then GATK for SNVs call. The NGS cost (from DNA extraction
to NGS data analysis), excluding personnel, is approximately 250€ for each FFPE, SF, and plasma
sample (A–C). The NGS turnaround time for processing SF (B) and no-WGA cfDNA (C) samples is
approximately five days, whereas f r FFPE (A) and WG cfD A (C) sample one more day is required
for the multiplex PCR DNA quality control (A) and WGA technique (C).
Pre-analytic quality control to define suitable DNA for NGS application is crucial, particularly
when it is applied to highly degraded DNA, such as FFPE DNA. The majority of studies, aimed to define
FFPE deep sequencing guidelines, focused on the correct DNA quantification method [19,20], whereas
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our workflow, which involves a multiplex-PCR approach, defined an AYR parameter, indicative of
gDNA degradation status, that highly correlates with sequencing quality metrics, such as uniformity
and coverage. Notably, we identified an integrity threshold for the processing of FFPE gDNAs
estimated at 0.3 AYR, which corresponds to 70% of gDNA fragmentation. Moreover, although the
library protocol requires 10 ng of input FFPE gDNA, we demonstrated that when doubling the input
FFPE DNA amount (20 ng), highly fragmented DNAs up to 0.3 AYR were successfully sequenced.
Notably, this improvement increased the number of amplicons covered to at least 500ˆ, a parameter
required for any clinically-oriented cancer panel [18]. However, we identified five recurrent amplicons
that were insufficiently covered in highly-degraded FFPE gDNAs because of high GC content (>60%),
as previously reported [21].
One critical point of the NGS analysis is generating a list of trustworthy variants; therefore,
we tested whether the integration of two different bioinformatic pipelines could improve the SNVs
call with higher sensitivity and accuracy compared with single software performance. Specifically,
we compared the VC, the Ion PGM plugin with optimized pre-set parameters, with GATK, one
of the most used free NGS tools. Each pipeline showed different results in the detection of SNVs
(100 SNVs by VC vs. 103 by GATK (95 in common between the two pipelines). Differences between
the pipelines could be due to the different alignment and calling algorithms [22]. Furthermore, the
GATK software exhibited a very high error rate in indel calling (approximately 20 indels per sample;
data not shown), leading us to exclude it in the indel calling. A possible explanation is that the GATK
pipeline was developed for Illumina data analysis, in contrast to the VC pipeline that has been set up
for the analysis of FastQ data generated from Ion-platforms [23]. In this context, some evidence has
been previously reported regarding the high rate of false positive variants detected by GATK with non
Illumina-FastQ data. These false positives particularly refer to small insertions and deletions (indels)
in homopolymeric regions where the difficulty in detecting and determining the genotype of short
indels remains a challenge because of the propensity for polymerase slipping during PCR, resulting in
sequence artifacts that GATK cannot distinguish [24]. The validation with the PS confirmed all VC
discordant genetic variants between SF and matching FFPE samples (>5% frequency), demonstrating
that the VC pipeline is optimized for Ion PGM data. Indeed, these discordant variants among SF
and matching FFPE samples may be explained by intra-tumor heterogeneity, as previously observed
in NSCLC [25–29]. Although the integration of GATK did not exclude any false positive SNVsby
VC, it removed all the SF/FFPE discordant SNVs detected by the VC pipeline with frequencies less
than 5%, confirming our LOD assay.
EGFR and KRAS somatic mutations, previously detected by SS, were confirmed by both pipelines
either in SF and matched FFPE, validating the high specificity of the Ion AmpliSeq Colon and Lung
Cancer panel for the identification of these mutations. Our data revealed that TP53 was the most frequent
pathogenically-mutated gene [30,31], and all patients harbored the SNP rs1042522 in TP53. Interestingly,
this SNP, responsible for a substitution of a proline residue with an arginine residue in codon 72 of TP53,
has been associated with lung cancer susceptibility [32] and a risk of toxicity during platinum-based
chemotherapy treatment in advanced NSCLC patients [33]. Notably, we also observed a recurrent
association between MET genetic variants and KRAS activating mutations, as already described in
NSCLC by Govindan et al. [34]. Due to its high sensitivity, NGS represents an optimal approach to
investigate the mutational profile of cfDNA as a non-invasive diagnostic approach to monitor disease
progression during treatment. Indeed, a fraction of cfDNA derives from tumor cells and is referred to as
ctDNA in cancer patients [35]. To date, several studies have demonstrated the feasibility of using ctDNA
as a potential tumor marker in a limited number of patients with various solid cancers; however, few
studies focused on NSCLC have been performed [9]. Therefore, we developed an optimized workflow for
cfDNA mutational screening, combining a WGA approach for low input samples (<1 ng) and a specific
protocol for sequencing library construction, resulting in high numbers of good-quality reads. Currently,
several WGA approaches, differing in assay chemistry and complexity, have been developed [36–40].
Here, we used a WGA based on the MDA technology that employs the phi29 DNA polymerase and
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random primers to amplify gDNA without thermocycling [40,41]. Several studies revealed that MDA
can amplify the genome with higher uniformity, longer length, and less bias compared with PCR-based
WGA methods [41–45]. Therefore, MDA-based WGA has been shown to be the best method to obtain
high quality cfDNA for different applications, such as the NGS [44,46,47]. Another important concern
of the WGA approach is the correct quantification of the amplified DNA. Indeed, WGA techniques
report non-specific side products and residual WGA reagents that may influence DNA quantification
by fluorometric methods [43,48]. Therefore, we suggested performing WGA-DNA quantification using
real-time PCR, which has been demonstrated to be the most reliable method [49]. The sequencing output
obtained from the WGA NCI-H1650 displayed a similar performance to the standard no-WGA cell line,
irrespective of input gDNA. Similar SNV frequencies were reported across the WGA NCI-H1650 samples,
suggesting that this technology may be applied to the colon and lung assay when the starting gDNA
amount is limited. However, it should be taken into account that the MDA-based WGA introduces
some amplification biases that mainly occur in DNA homopolymeric regions, as previously observed,
resulting in a lower specificity of the assay [41,50,51]. Because the WGA application might be necessary
to yield sufficient DNA for the subsequent sequencing workflow [52], we tried to limit all critical points.
Our optimized workflow and NGS analysis on cfDNAs allowed for detection of the same mutational
profile of the corresponding tumor in one cfDNA sample. However, among nine NSCLC patients with
available plasma, only two were at stage IV of disease. Because several studies revealed that the presence
of ctDNA was mainly detected in aggressive disease [9,53], this observation could explain why we
detected ctDNA in only one of two patients with advanced NSCLC. The unidentified somatic mutations
in localized (stage I–III) cfDNA samples could also be explained by the detection limit of mutation allele
frequencies of our NGS assay, estimated at 5% [54].
However, since the Ion PGM technology utilizes scalable semiconductor chips, a lower number of
samples in the same run could increase the amplicon coverage; this might allow for the detection of
variants with lower frequency (<5%) in the hypothesis to also apply the NGS workflow to the ctDNA
screening. Such higher throughput, might also permit us to detect tumor heterogeneity e.g., in the
profiling of ctDNA and to call variants at very low frequencies. Furthermore, since the correct amplicon
size is critical to the success of sequencing experiments, designing custom panels with a shorter length
of amplicons could improve the sequencing performances, especially for highly fragmented DNA such
as FFPE and cfDNA. Finally, it should be kept in mind that customizing panels for a subset of druggable
genes of a specific cancer type may offer testing at a lower cost, thereby yielding a higher coverage.
4. Experimental Section
4.1. Sample Collection
Twelve patients who underwent surgery for NSCLC at different stage of the disease were enrolled
in our study as the “Training Set”, based on their previously known EGFR and KRAS mutational
statuses. The clinical characteristics of the patients are reported in Table 2. SF tumors from all patients
were available in the tissue biobank of our Institute. Additionally, matched FFPE tissues were obtained
from the pathology archive. All samples were evaluated by a pathologist for malignant cell content
to macrodissect and enrich the tumor component up to 50%, when necessary. Nine of the 12 plasma
samples from patients were also collected at time of diagnosis.
We also enrolled a further 13 NSCLC patients as the “Validation Set” (Table 3), and for each
case the FFPE tissue block was revised by the pathologist to verify the tumor cell content. Moreover,
three Horizon FFPE standards (EGFR p.Thr790Met, EGFR p.Glu746_Ala750del, and EGFR wild-type
reference standards; Horizon, Cambridge, UK) and two human NSCLC cell lines (NCI-H1650
p.Glu746_Ala750del and NCI-H1975 p.Thr790Met/p.Leu858Arg; American Type Culture Collection,
Manassas, VA, USA) were used to assess the parameter performances of our assay. The present study
was approved by the local ethics committee (TP-01-2014; 255REG2014) and written informed consent
was obtained from every patient.
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Table 2. Clinical characteristics of NSCLC (Non-small cell lung cancer) in the “Training Set”.
Patient Block Age % TC SF FFPE cfDNA Histology TNM Stage Age at Diagnosis G Smoking Habits PS OS Status
1 2012 >50 x x x SCC T1b, N0, M0 IA 77 M S 1 30 A
2 2010 >50 x x x ADK T1a,N2,M0 IIIA 67 M NS 1 18 DOD
3 2013 >50 x x x ADK T2, N2, M1a IV 76 F NS 1 14 DOD
4 2010 >50 x x x ADK T2b,N0,MX IIA 76 M FS 1 11 DOD
5 2013 >50 x x NA ADK T2a,N2,M1b IV 75 F NS 1 13 A
6 2011 >50 x x NA ADK T2a, N0, MX IB 78 F NS 1 29 DOD
7 2013 >50 x x x ADK T2a, N2, M1b IV 65 M S 1 3 DOD
8 2013 >50 x x x ADK T2b, N1, M0 IIB 59 F S 1 23 A
9 2012 >50 x x x ADK T2a, N0, MX IB 72 M FS 0 28 A
10 2011 >50 x x NA ADK T2b, N0, M0 IIB 66 F FS 1 42 A
11 2010 >50 x x x ADK T1a, N0, M0 IA 77 M FS 0 49 DOD
12 2010 >50 x x x ADK T1a, N0, M0 IA 60 F S 1 32 DOD
Table 3. Clinical characteristics of NSCLC patients in the “Validation Set”.
Patient Block Age % TC SF FFPE cfDNA Histology TNM Stage Age at Diagnosis G Smoking Habits PS OS Status
13 2015 >50 NA x NA ADK T2, N2, M0 IIIB 59 M S 0 5 A
14 2014 >50 NA x NA ADK Tx, Nx, M1a IV 42 M NS 0 14 A
15 2015 >50 NA x NA ADK T3, N3, M1a IV 64 M FS 1 4 A
16 2014 >50 NA x NA ADK T4, N2, M1b IV 77 F NS 0 12 A
17 2014 >50 NA x NA ADK T3, N2, M0 IIIA 70 F NS 1 8 A
18 2012 >50 NA x NA ADK T3, N2, M1b IV 63 M S 1 37 A
19 2014 >50 NA x NA ADK T4, N2, M1b IV 70 M FS 1 2 DOD
20 2014 >50 NA x NA ADK T4, N0, M0 IIIA 68 M FS 0 16 A
21 2011 >50 NA x NA ADK T1a, N0, M0 IA 71 F NS 1 42 DOD
22 2014 >50 NA x NA ADK T2, N2, M1b IV 81 F NS 1 10 DOD
23 2013 >50 NA x NA ADK T1b, N2, M0 IIIA 72 M FS 1 22 A
24 2014 >50 NA x NA ADK T3, N3, M1b IV 61 M NS 1 11 DOD
25 2015 >50 NA x NA ADK Tx, Nx, M1b IV 55 F FS 0 7 A
Abbreviations: TC: Tumor Content; ADK: Adenocarcinoma; SCC: squamous cell carcinoma; TNM: Tumor-Nodes-Metastasis; G: Gender; F: Female; M: Male; S: Smoker; NS: never
smoker; FS: Former smoker; PS: Performance Status; OS: Overall Survival (Month); A: Alive; DOD: Dead of disease; x: present; NA: not available.
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4.2. DNA Extraction and Quality Control
gDNA from SF samples and the NCI-H1650 cell line was isolated using a QIAampr DNA
Mini Kit (Qiagen, Hilden, Germany), whereas gDNA from FFPE tissues was extracted using the
GeneRead DNA FFPE Kit (Qiagen), according to the manufacturer’s recommendations. All gDNA
samples were then quantified by a Qubitr 2.0 Fluorometer (Invitrogen, Carlsbad, CA, USA) using a
Qubitr dsDNA HS Assay Kit. cfDNA was extracted from 400 µL of plasma with a QIAamp DNA
Blood Mini Kit (Qiagen) and quantified by quantitative PCR (qPCR) using the human telomerase
reverse transcriptase (hTERT) TaqManr Copy Number Reference Assay (Catalog: 4403316; Life
Technologies). The calibration curve was defined based on a dilution series (10–1 ˆ 106 pg) of
a control human genomic DNA standard (Promega, Madison, WI, USA). The qPCR reaction was
performed in a final reaction volume of 10 µL using 5 µL of TaqMan Universal Mastermix (Life
Technologies, Carlsbad, CA, USA), 1 µL of the TaqManr Copy Number Reference Assay hTERT (Life
Technologies), and 4 µL of cfDNA on a RealPlex (Eppendorf, Hamburg, Germany) device. Each
sample was run in duplicate, and the final concentration calculated by interpolation of the CT value
with the aforementioned calibration curve. Both SF and FFPE gDNA underwent a quality control
assay. DNA quality was first assessed using a NanoDrop ND-1000 (Thermo Scientific, Wilmington,
DE, USA) to measure the whole absorption spectrum (220–750 nm) and calculating absorbance ratios
at both 260/280 and 260/230. SF gDNA was analyzed on 0.8% agarose gel electrophoresis to visualize
the DNA size distribution, whereas we performed a multiplex PCR-based quality control assay
using a slight modification of the van Beers et al. [55] protocol to assess FFPE gDNA fragmentation
status. Briefly, 30 ng of FFPE gDNA, as measured by Qubit, was analyzed by a multiplex PCR
reaction performed using three independent sets of GAPDH primers that amplify 200, 300, and
400 bp fragments. The amplification was performed in a reaction volume of 30 µL with final
concentrations of 0.133 µM of each primer, 1.5 U AmpliTaq Goldr DNA Polymerase (Life Technologies,
Carlsbad, CA, USA), GeneAmpr 10ˆ PCR Gold Buffer, 1.5 mmol/L MgCl2, and 0.2 mmol/L
dNTPs. PCR was conducted in a Mastercyclerr nexus Thermal Cycler (Eppendorf) as follows: 95 ˝C
for 7 min, 35 cycles of 1 min at 94 ˝C, 1 min at 56 ˝C, and 3 min at 72 ˝C, followed by a hold at 72 ˝C
for 7 min. PCR products were then analyzed with an Agilent 2100 Bioanalyzer using the Agilent High
Sensitivity DNA Kit (Agilent Technologies, Santa Clara, CA, USA). The yield of the resulting three
amplicons was evaluated by comparison with the yield of amplicons from a reference DNA template
(Promega). The Average Yield Ratio (AYR), calculated for each amplicon, was used as a quantitative
indicator of FFPE DNA integrity.
4.3. Whole Genome Amplification (WGA)
cfDNA less than 1 ng, estimated by qPCR, underwent WGA using the REPLI-g Single Cell Kit
(Qiagen). The REPLI-g Single Cell Kit is based on a Multiple Displacement Amplification (MDA)
technology that achieves highly uniform amplification across the entire genome with minimal locus
bias and reduced nonspecific amplification artefacts [41]. To evaluate the performance of this assay for
subsequent NGS application, we previously amplified a scalar dilution of NCI-H1650 cell line gDNA
(10, 1, and 0.1 ng). The amplified gDNAs were diluted 1:100 and evaluated by qPCR using the hTERT
assay, as previously described.
4.4. Next Generation Sequencing (NGS)
Libraries were amplified using the Ion AmpliSeq Colon and Lung Cancer Panel v.1
(Life Technologies), which analyzes 90 amplicons in hotspots and target regions of 22 genes (AKT1, ALK,
BRAF, CTNNB1, DDR2, EGFR, ERBB2, ERBB4, FBXW7, FGFR1, FGFR2, FGFR3, KRAS, MAP2K1, MET,
NOTCH1, NRAS, PIK3CA, PTEN, SMAD4, STK11, and TP53) with a coverage of over 500 mutations
involved in colon and lung cancers. Overall, 20 ng for FFPE, 10 ng for SF gDNA and WGA cfDNA, and
a range from 1 to 10 ng for no-WGA cfDNA were amplified using the Ion AmpliSeq™ Library Kit 2.0
28776
Int. J. Mol. Sci. 2015, 16, 28765–28782
(Life Technologies), barcoding each sample. Different cycling conditions were performed according to
the DNA type: 22 cycles for FFPE gDNA and no-WGA cfDNA and 19 cycles for SF gDNA and WGA
cfDNA in the first multiplex PCR, whereas in the second, optional PCR, the SF, FFPE and WGA cfDNA
were subjected to five cycles, and the no-WGA cfDNA underwent seven cycles.
The library size was checked using the Agilent High Sensitivity DNA Kit by the Bioanalyzer 2100
instrument (Agilent Technologies), and library concentration was evaluated with a Qubitr 2.0
Fluorometer using the Agilent High Sensitivity DNA Kit (Life Technologies). Each diluted library
(100 pM) was amplified through emulsion PCR using the OneTouch™ Instrument (Life Technologies)
and enriched by the OneTouch™ ES Instrument (Life Technologies) using the Ion PGM Template
OT2 200 KIT, following the manufacturer’s instructions. Finally, sequencing was performed on the Ion
PGM (Life Technologies) with the Ion PGM 200 Sequencing Kit (Life Technologies), loading barcoded
samples into a 314v.2 or 316v.2 chip.
4.5. NGS Data Analysis
The PGM sequencing data were analyzed by the Ion Torrent Software Suite v.4.2
(Life Technologies) using the plugin Variant Caller (VC) v.4.2-r88446. Hotspot and targeted regions,
together with the json parameters files associated with the Ion AmpliSeq Colon and Lung Cancer
Panel v.1 (Life Technologies), were then loaded into the VC plugin. All identified variants were
visually confirmed by the Integrative Genomics viewer (IGV) [56]. To validate data, a second round
of analysis was performed as follows: FastQ data, generated by the Ion PGMTM semiconductor,
were aligned to the Hg19 genome reference using BWA (Burrows-Wheeler Alignment)-MEM tool
optimized for 70 bp–1 Mb long reads. Then, the resulting SAM (Sequence Alignment Map) files
were converted and sorted to the BAM (binary version of SAM) format by SAMtools. Post-alignment
steps included local realignment in the proximity of known indels and recalibration of the quality
score, both performed by the Genome Analysis Toolkit (GATK) 2.5 Unified Genotyper (Realigner
Target Creator, Indel Realigner and Base Recalibrator options) starting from sorted BAM files. Finally,
GATK called variants in the target regions included in the BED file with Phred scores greater than
5 (those with a Phred score between 5 and 30 were marked as low-quality variants). Only Single
Nucleotide Variants (SNVs) were considered, annotated by SNPEff, and compared to those called
with the Ion Reporter™ tool [57]. All the samples belonging to the same patients were analyzed in
multi-sample mode. Variants were annotated using the PolyPhen-2) [58], SIFT [59], and Genomic
Evolutionary Rate Profiling (GERP) tools to predict the effect of missense mutations on the protein and
calculate their conservation scores. Additionally, variants were named according to the Catalogue of
Somatic Mutation in Cancer (COSMIC) [13] and Single Nucleotide Polymorphism Database (dbSNP).
To distinguish common polymorphisms from rare variants, Global Minor Allele Frequency (GMAF)
was calculated using the allele frequencies across all 1000 Genomes Phase I populations [60].
4.6. NGS Parameter Performance
To assess the performance parameters of our assay, two NSCLC cell lines and two DNA FFPE
reference standards were sequenced according to our workflow. NGS data from the cell lines
(NCI-H1650 and NCI-1975) were compared to genotypes obtained from published NGS data using Ion
AmpliSeq™ Cancer Panel on Ion PGM sequencer (Life Technologies) [61]. Similarly, the data from the
two FFPE reference standards were compared to genotype assessed by Horizon using droplet digital
PCR. We also evaluated the performance parameters of our assay on WGA samples by comparing
the mutation profiles of WGA amplified of NCI-H1650 scalar dilutions (10, 1, and 0.1 ng) with the
corresponding unamplified cell line. The sensitivity, specificity, and PPV of the tests were calculated
as described [62] and confidence intervals were calculated using the Confidence Interval Calculator
(accessed on 1 February 2015).
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4.7. Sanger Sequencing (SS) and Pyrosequencing (PS)
NGS variants with frequencies higher than 20% were validated by SS, using the specific gene
primer of the panel as described by Coco (2012) [63]. Genetic variants with a frequency range
from 5% to 20% were validated by PS. The primer sets for the PS assays (which include a PCR
primer pair and a sequencing primer) were designed with the Pyrosequencing Assay Design software
(Biotage, Uppsala, Sweden). All the primer sequences, the PCR amplification conditions, and the
sequence to analyze are reported in Supplementary Table S5. The PCR reactions were performed
by amplifying 100 ng of gDNA in a final volume of 50 µL containing 200 mol/L dNTPs, 1ˆ Taq
buffer, 1.5 mM MgCl2, 0.2 µM of each PCR primer, 1.5 U of AmpliTaq Goldr DNA Polymerase
(Life Technologies). The PCR program consists of 10 min at 95 ˝C and 45 cycles with 30 s
at 95 ˝C, 30 s at specific annealing temperature of primer, and 30 s at 72 ˝C, followed by 5 min at 72 ˝C.
The PS assays were performed with a PSQ 96MA instrument (Qiagen); the sequencing reactions were
performed with the Pyro Gold reagent kit PSQ 96MA, according to the manufacturer’s instructions,
and the sequencing analysis conducted with the PSQTM 96MA software v.2.02 (Biotage AB,
Uppsala, Sweden).
5. Conclusions
In conclusion, here we demonstrate the feasibility of obtaining DNA suitable for NGS from FFPE
tissues by performing an appropriate DNA quality control assay based on a multiplex PCR. Indeed,
adequate quality control of extracted DNA represents the most critical step of the entire procedure and
in particular gDNA from an FFPE biopsy, which is highly fragmented and limited. The assessment of
the suitability of the starting DNA for subsequent sequencing is mandatory for reducing the time and
costs of the downstream processes due to a possible sequencing failure.
In particular, our NGS-based workflow was successfully able to screen critical samples, such as
FFPE tissues, demonstrating the possibility of transferring this novel technology into routine clinical
context. Our criterion for considering a variant as true positive was a variant allele frequency greater
than 5% with coverage higher than 500ˆ.
We also report that VC is a reliable software program for identifying SNVs and indels using
Ion PGM NGS data, that streamline and simplify the data analysis, annotation, and reporting of
data, reducing the time to results. However, a second round of variant calling by GATK software is
suggested, particularly in a starting setup. The inclusion of a reference standard, harboring mutation
with AF at 5%, to sequence in each run as well as a validation step with an independent test to confirm
clinically actionable mutations, are recommended to confidently call mutations in a clinical contest.
We also report a feasible sequencing workflow by starting from low-input gDNA to be applicable
in the detection of ctDNA mutational profiles. However, to translate this technology into the disease
monitoring and treatment of NSCLC, further validation studies on a greater number of samples,
specifically on cfDNA from metastatic NSCLC patients, are required.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/16/
12/26129/s1.
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